164 related articles for article (PubMed ID: 18034311)
41. In Silico Prediction of Cytochrome P450-Drug Interaction: QSARs for CYP3A4 and CYP2C9.
Nembri S; Grisoni F; Consonni V; Todeschini R
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27294921
[TBL] [Abstract][Full Text] [Related]
42. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
43. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
44. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.
Yale SH; Glurich I
J Altern Complement Med; 2005 Jun; 11(3):433-9. PubMed ID: 15992226
[TBL] [Abstract][Full Text] [Related]
45. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
46. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9.
Kent UM; Aviram M; Rosenblat M; Hollenberg PF
Drug Metab Dispos; 2002 Jun; 30(6):709-15. PubMed ID: 12019199
[TBL] [Abstract][Full Text] [Related]
47. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
Kudo S; Odomi M
Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
[TBL] [Abstract][Full Text] [Related]
48. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.
Venkatakrishnan K; Greenblatt DJ; von Moltke LL; Schmider J; Harmatz JS; Shader RI
J Clin Pharmacol; 1998 Feb; 38(2):112-21. PubMed ID: 9549641
[TBL] [Abstract][Full Text] [Related]
49. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
50. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.
Niwa T; Shiraga T; Takagi A
Biol Pharm Bull; 2005 Sep; 28(9):1805-8. PubMed ID: 16141567
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
52. Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
Roy K; Roy PP
Eur J Med Chem; 2009 May; 44(5):1941-51. PubMed ID: 19110342
[TBL] [Abstract][Full Text] [Related]
53. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
54. Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.
Eng H; Obach RS
Drug Metab Dispos; 2016 Aug; 44(8):1217-28. PubMed ID: 27271369
[TBL] [Abstract][Full Text] [Related]
55. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.
Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D
Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000
[TBL] [Abstract][Full Text] [Related]
56. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Taguchi K; Konishi T; Nishikawa H; Kitamura S
Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
[TBL] [Abstract][Full Text] [Related]
57. In vitro identification of cytochrome P450 enzymes responsible for drug metabolism.
Yan Z; Caldwell GW
Methods Mol Biol; 2013; 1015():251-61. PubMed ID: 23824861
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
[TBL] [Abstract][Full Text] [Related]
59. Succinic acid inhibits the activity of cytochrome P450 (CYP450) enzymes.
Wang H; Xia B; Lin M; Wang Y; Sun B; Li Y
Pharm Biol; 2020 Dec; 58(1):1150-1155. PubMed ID: 33327821
[TBL] [Abstract][Full Text] [Related]
60. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.
Crewe HK; Ellis SW; Lennard MS; Tucker GT
Biochem Pharmacol; 1997 Jan; 53(2):171-8. PubMed ID: 9037249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
